Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes management.

Compounded vs non-compounded GLP-1 RA drug products are associated with an increased risk for adverse events such as nausea and diarrhea.

Improving access and affordability could be transformative for public health, given that about 88% of Americans are ...

People undergoing metabolic and bariatric surgery are less likely to develop psychiatric disorders than those treated with GLP-1 RAs.

GLP-1 receptor agonists may increase the risk of several autoimmune diseases in adults with type 2 diabetes, according to ...

The UK's medicines regulator has launched a study to investigate the impact of these drugs following reports of people dying ...

This innovation is led by the need for greater patient compliance and user-friendliness, portending an era of more convenient ...

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

Hundreds of people have reported problems with their pancreas linked to taking weight loss and diabetes jabs, prompting ...

There are two ways in which industry can respond to the GLP-1 craze. On the one hand, they can, like Nestlé, create smaller ...

GLP-1 medicines are licensed for Type 2 diabetes and weight management, and include the branded products Ozempic, Mounjaro ...

A 6-week randomized trial found that tirzepatide significantly reduced energy intake, appetite, and cravings in adults with ...